Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds ‘Apple’s iPhone 14 launch event will take place on September 7th’ – The Verge

News

‘Apple’s iPhone 14 launch event will take place on September 7th’ – The Verge

https://www.theverge.com/2022/8/24/23310522/apple-iphone-14-event-announcement-date-time-september-2022

byBenzinga Newsdesk

August 24, 2022

1 minute read

https://www.theverge.com/2022/8/24/23310522/apple-iphone-14-event-announcement-date-time-september-2022

Geely’s EV Brand Zeekr Pursues $1B In US IPO: Report

By Shivani Kumaresan

December 12, 7:05 AM

Chinese automotive company Geely Automobile Holdings Ltd's (OTC: GELYY) (OTC: GELYF) premium electric car division, Zeekr, has filed for a U.S. initial public offering (IPO).

GELYF

Laser Photonics Says On Jan. 9, Board Authorized Initiation Of Share Repurchase Program To Purchase Up To 2M Shares Of Common Stock

By Michael Horton

January 10, 6:05 PM

-SEC Filing

LASE

Co-Diagnostics, Inc. Initiates Clinical Evaluations For Its At-Home And Point-Of-Care Co-Dx PCR Home Platform

By Happy Mohamed

February 22, 10:32 AM

Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced

CODX

Blue Bird Q4 EPS $(0.66) Misses $0.04 Estimate, Sales $257.67M Beat $221.70M Estimate

By Benzinga Newsdesk

December 12, 5:00 PM

Blue Bird (NASDAQ:BLBD) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $0.04 by 1750 percent. This is a 1042.86 percent decrease over earnings of $0.07 per share from the

BLBD

‘Apple’s iPhone 14 launch event will take place on September 7th’ – The Verge

Related Posts

Geely’s EV Brand Zeekr Pursues $1B In US IPO: Report

Laser Photonics Says On Jan. 9, Board Authorized Initiation Of Share Repurchase Program To Purchase Up To 2M Shares Of Common Stock

Co-Diagnostics, Inc. Initiates Clinical Evaluations For Its At-Home And Point-Of-Care Co-Dx PCR Home Platform

Blue Bird Q4 EPS $(0.66) Misses $0.04 Estimate, Sales $257.67M Beat $221.70M Estimate